title: Pharmacokinetics of budesonide controlled ileal release capsules in children and adults with active Crohn's disease.
abstract: BACKGROUND
  Systemic glucocorticosteroid therapy is effective in Crohn's disease, but is associated with side-effects. Budesonide has high topical anti-inflammatory activity, but considerably lower systemic activity than other oral glucocorticosteroids.
  
  
  OBJECTIVE
  To evaluate the systemic exposure to budesonide (controlled ileal release capsules) in children and adults with active Crohn's disease, and to assess the suppression of plasma cortisol.
  
  
  METHODS
  In an open label study, patients (eight children and six adults) with active Crohn's disease received 9 mg budesonide (Entocort capsules) orally once daily for 7 days. Plasma concentrations were determined on the seventh day of administration, and pharmacokinetic parameters were calculated. For reference, 0.5 mg budesonide was given intravenously separately. Plasma cortisol levels were compared with the pre-treatment baseline values.
  
  
  RESULTS
  Systemic exposure to budesonide (AUC0-24 h) after 1 week of oral administration was 41 +/- 21 nmol/L x h (mean +/- s.d.) in children and 35 +/- 20 nmol/L x h in adults. The estimated systemic availability in children was 9 +/- 5% and in adults 11 +/- 7%. The mean plasma cortisol (AUC0-24 h) decreased by 64 +/- 18% in children and by 50 +/- 27% in adults.
  
  
  CONCLUSIONS
  The systemic exposure, systemic availability and cortisol suppression after oral administration of 9 mg budesonide were similar in children and adults with active Crohn's disease. Budesonide was well tolerated and no clinically important safety-related findings were identified.
authors.affiliation: Experimental Medicine, Astra-Zeneca R & D Mölndal, S-431 83 Mölndal, Sweden. pal.lundin@astrazeneca.com
authors.forename: P D P
authors.initials: PD
authors.lastname: Lundin
authors.forename: S
authors.initials: S
authors.lastname: Edsbäcker
authors.forename: M
authors.initials: M
authors.lastname: Bergstrand
authors.forename: J
authors.initials: J
authors.lastname: Ejderhamn
authors.forename: H
authors.initials: H
authors.lastname: Linander
authors.forename: L
authors.initials: L
authors.lastname: Högberg
authors.forename: T
authors.initials: T
authors.lastname: Persson
authors.forename: J C
authors.initials: JC
authors.lastname: Escher
authors.forename: B
authors.initials: B
authors.lastname: Lindquist
mesh_terms: D000284:Administration, Oral; D000293:Adolescent; D000328:Adult; D000893:Anti-Inflammatory Agents / Q000008:administration & dosage / Q000009:adverse effects / Q000493:pharmacokinetics*; D019819:Budesonide / Q000008:administration & dosage / Q000009:adverse effects / Q000493:pharmacokinetics*; D002214:Capsules; D002648:Child; D003424:Crohn Disease / Q000097:blood / Q000188:drug therapy*; D003692:Delayed-Action Preparations; D005260:Female; D006801:Humans; D006854:Hydrocortisone / Q000097:blood; D007262:Infusions, Intravenous; D008297:Male
chemical_list: D000893:Anti-Inflammatory Agents; D002214:Capsules; D003692:Delayed-Action Preparations; D019819:Budesonide; D006854:Hydrocortisone